Revatio (Sildenafil Citrate) Patent Expiration, LOE Window & CMS Spending

Revatio (Sildenafil Citrate) by Viatris: FDA Orange Book LOE 2030-01-31, 26 AB generics, $31.9M 2024 CMS Part D & Medicaid spend, and 5 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorViatris
FDA Application & PathwayN021845 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2030-01-31
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors26
2024 CMS Total Public Spend$31.9M
2024 Medicare Part D Spend$7.2M
2024 Medicaid Spend$24.7M
Reported Wholesale Price Change (CA SB 17)5 WAC filings (max 17.9% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Viatris across sibling Meru public-data platforms.